bladder cancer
Conditions
Interventions
Gold Standard:Cystoscope and related pathological diagnosis
Index test:Urinary DNA
Sponsors
Department of Urology, Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Suspected bladder cancer patient with signs and symptoms of urinary tract inflammation (painless gross hematuria, urine routine occult blood, frequency of urination, urgency of urination, pain in urination, etc.), age > 18 years old. 2. The clinical samples of each clinical trial object should be fresh and sufficient for examination reagent and routine urine test. 3. All samples are from outpatient or inpatient specimens of clinical hospitals, and all samples must have clinical diagnosis or pathological diagnosis. 4.All samples should have corresponding basic clinical information, including sample ID number (outpatient number, medical record number, contact information and hospital number), gender, age, smoking history, chemical exposure history, family history of bladder cancer and clinical diagnosis information. 5. Control cases of other urinary tract diseases other than bladder cancer (which were eventually clinically diagnosed as non-bladder cancer), including prostatic hyperplasia, urinary tract stones, urinary tract infection, kidney cancer, etc.
Exclusion criteria
Exclusion criteria: 1. Sample number (outpatient number, medical record number or hospital number, etc.), gender, age, clinical diagnosis and other information missing. 2. Samples are not fresh. 3. The sample size is not enough to complete all the test samples. 4. Other samples that do not meet the basic requirements of examination reagent or comparison method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary DNA;Urinalysis;SPE, SEN, ACC;methylation; | — |
Countries
China
Contacts
Public ContactLong Wang
Department of Urology, Xiangya Hospital, Central South University
Outcome results
None listed